Share on StockTwits

Quest Diagnostics (NYSE:DGX) will announce its Q114 earnings results on Thursday, April 24th. Analysts expect the company to announce earnings of $0.89 per share and revenue of $1.75 billion for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, January 30th. The company reported $0.97 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.93 by $0.04. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.74 billion. On average, analysts expect Quest Diagnostics to post $4.04 EPS for the current fiscal year and $4.34 EPS for the next fiscal year.

Quest Diagnostics (NYSE:DGX) opened at 58.40 on Wednesday. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock’s 50-day moving average is $56.8 and its 200-day moving average is $56.70. The company has a market cap of $8.428 billion and a price-to-earnings ratio of 10.71.

DGX has been the subject of a number of recent research reports. Analysts at Credit Suisse raised their price target on shares of Quest Diagnostics from $55.00 to $62.00 in a research note on Monday, April 14th. On the ratings front, analysts at Goldman Sachs raised their price target on shares of Quest Diagnostics from $61.00 to $67.00 in a research note on Friday, April 11th. Finally, analysts at Mizuho raised their price target on shares of Quest Diagnostics from $54.00 to $63.00 in a research note on Wednesday, April 2nd. They now have a “neutral” rating on the stock. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $59.39.

Quest Diagnostics Incorporated (NYSE:DGX), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.